Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement—Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors

INTRODUCTION: Although driver gene mutations have been believed to be mutually exclusive, some patients with NSCLC and concomitant EGFR mutations and EML4-ALK rearrangements have been reported. In this study, we reported a case of a patient with lung cancer who harbored both EGFR mutation and the EM...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Ming-Hung, Lee, Jih-Hsiang, Hung, Pei-Shan, Chih-Hsin Yang, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618994/
https://www.ncbi.nlm.nih.gov/pubmed/36325153
http://dx.doi.org/10.1016/j.jtocrr.2022.100405

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9618994/
https://www.ncbi.nlm.nih.gov/pubmed/36325153
http://dx.doi.org/10.1016/j.jtocrr.2022.100405

Ejemplares similares